K
Kayo Ichihashi
Researcher at University of Tokyo
Publications - 29
Citations - 189
Kayo Ichihashi is an academic researcher from University of Tokyo. The author has contributed to research in topics: Medicine & Schizophrenia (object-oriented programming). The author has an hindex of 5, co-authored 9 publications receiving 38 citations.
Papers
More filters
Journal ArticleDOI
Improvement of psychiatrists’ clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the ‘Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)’ project: A nationwide dissemination, education, and evaluation study
Yoshikazu Takaesu,Koichiro Watanabe,Shusuke Numata,Masaaki Iwata,Noriko Kudo,Satoru Oishi,Takeya Takizawa,Kiyotaka Nemoto,Yuka Yasuda,Hiromi Tagata,Takashi Tsuboi,Naohisa Tsujino,Naoki Hashimoto,Yuki Matsui,Hikaru Hori,Hidenaga Yamamori,Nobuhiro Sugiyama,Taro Suwa,Taishiro Kishimoto,Akitoyo Hishimoto,Masahide Usami,Ryuji Furihata,Kunihiro Iwamoto,Hiroshige Fujishiro,Hiroshige Fujishiro,Toshinori Nakamura,Kentaro Mizuno,Takahiko Inagaki,Eiichi Katsumoto,Hiroaki Tomita,Kazutaka Ohi,Hiroyuki Muraoka,Kiyokazu Atake,Hitoshi Iida,Tatsuya Nagasawa,Junichi Fujita,Satoshi Yamamura,Toshiaki Onitsuka,Atsunobu Murata,Yoichiro Takayanagi,Hokuto Noda,Yukiko Matsumura,Kenji Takezawa,Jun-ichi Iga,Kayo Ichihashi,Kazuyoshi Ogasawara,Hisashi Yamada,Ken Inada,Ryota Hashimoto +48 more
TL;DR: The ‘Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE’ integrated education programs for psychiatrists to disseminate the clinical guidelines for schizophrenia and major depressive disorder are developed.
Journal ArticleDOI
Prescription patterns in patients with schizophrenia in Japan: First-quality indicator data from the survey of "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" project.
Kayo Ichihashi,Hikaru Hori,Naomi Hasegawa,Yuka Yasuda,Tomoya Yamamoto,Takashi Tsuboi,Kunihiro Iwamoto,Taishiro Kishimoto,Tadasu Horai,Hiroki Yamada,Nobuhiro Sugiyama,Nobuhiro Sugiyama,Toshinori Nakamura,Naohisa Tsujino,Kiyotaka Nemoto,Satoru Oishi,Masahide Usami,Eiichi Katsumoto,Hidenaga Yamamori,Hiroaki Tomita,Taro Suwa,Ryuji Furihata,Takahiko Inagaki,Junichi Fujita,Toshiaki Onitsuka,Kenichiro Miura,Junya Matsumoto,Kazutaka Ohi,Kazutaka Ohi,Yuki Matsui,Yoshikazu Takaesu,Naoki Hashimoto,Jun-ichi Iga,Kazuyoshi Ogasawara,Hisashi Yamada,Koichiro Watanabe,Ken Inada,Ryota Hashimoto +37 more
TL;DR: The quality indicator values of prescription before the beginning of the guideline lectures in the EGUIDE project are reported to ascertain the baseline status of treating patients with schizophrenia.
Journal ArticleDOI
Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project
Naoki Hashimoto,Norio Yasui-Furukori,Naomi Hasegawa,Shuhei Ishikawa,Shusuke Numata,Hikaru Hori,Hitoshi Iida,Kayo Ichihashi,Ryuji Furihata,Atsunobu Murata,Takashi Tsuboi,Masahiro Takeshima,Yoshitaka Kyou,Hiroshi Komatsu,Chika Kubota,Shinichiro Ochi,Yoshikazu Takaesu,Masahide Usami,Tatsuya Nagasawa,Akitoyo Hishimoto,Kenichiro Miura,Junya Matsumoto,Kazutaka Ohi,Hisashi Yamada,Ken Inada,Koichiro Watanabe,Kazutaka Shimoda,Ryota Hashimoto +27 more
TL;DR: In this paper, the authors collected prescription data at discharge from 2177 patients with schizophrenia and 1238 patients with major depressive disorder (MDD) from October 2016 to March 2018.
Journal ArticleDOI
Unmet needs of patients with major depressive disorder - Findings from the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' project: A nationwide dissemination, education, and evaluation study.
Hitoshi Iida,Jun-ichi Iga,Naomi Hasegawa,Yuka Yasuda,Tomoya Yamamoto,Kenichiro Miura,Junya Matsumoto,Atsunobu Murata,Kazuyoshi Ogasawara,Hisashi Yamada,Hikaru Hori,Kayo Ichihashi,Naoki Hashimoto,Kazutaka Ohi,Norio Yasui-Furukori,Takashi Tsuboi,Toshinori Nakamura,Masahide Usami,Ryuji Furihata,Yoshikazu Takaesu,Kunihiro Iwamoto,Nobuhiro Sugiyama,Taishiro Kishimoto,Naohisa Tsujino,Hiroki Yamada,Akitoyo Hishimoto,Kiyotaka Nemoto,Kiyokazu Atake,Hiroyuki Muraoka,Eiichi Katsumoto,Satoru Oishi,Takahiko Inagaki,Fumiaki Ito,Yayoi Imamura,Mikio Kido,Tatsuya Nagasawa,Shusuke Numata,Shinichiro Ochi,Masaaki Iwata,Hidenaga Yamamori,Junichi Fujita,Toshiaki Onitsuka,Satoshi Yamamura,Manabu Makinodan,Michiko Fujimoto,Yoichiro Takayanagi,Kenji Takezawa,Hiroshi Komatsu,Kentaro Fukumoto,Shinichiro Tamai,Hirotaka Yamagata,Chika Kubota,Tadasu Horai,Ken Inada,Koichiro Watanabe,Hiroaki Kawasaki,Ryota Hashimoto +56 more
TL;DR: It is confirmed that antidepressant polypharmacy prevailed in Japan, while this is the first report showing a large institutional difference and long-term benzodiazepine use is not recommended in the GL due to the potential side-effects.
Journal ArticleDOI
Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study
Ryuji Furihata,Rei Otsuki,Naomi Hasegawa,Takashi Tsuboi,Shusuke Numata,Norio Yasui-Furukori,Hiroko Kashiwagi,Hikaru Hori,Shinichiro Ochi,Hiroyuki Muraoka,Toshiaki Onitsuka,Hiroshi Komatsu,Masahiro Takeshima,Akitoyo Hishimoto,Tatsuya Nagasawa,Yoshikazu Takaesu,Toshinori Nakamura,Takeshi Asami,Kenichiro Miura,Junya Matsumoto,Kazutaka Ohi,Yuka Yasuda,Hitoshi Iida,Kazuyoshi Ogasawara,Naoki Hashimoto,Kayo Ichihashi,Hisashi Yamada,Koichiro Watanabe,Ken Inada,Ryota Hashimoto +29 more